ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company’s first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company’s global public policy, regulatory, and government affairs functions.

A former senior leader at the FDA, prosecutor for DOJ, and leader in the pharma industry and nonprofit sector, Deb Autor is a trusted visionary voice in health policy. She brings more than three decades of experience to help Hims & Hers ensure that innovation and integrity move hand in hand. Autor has played a key role in guiding Hims & Hers as a member of the Board of Directors since 2024.

“Extraordinary innovation in areas such as AI, robotics, and at-home diagnostics provides an opportunity to reshape how we deliver access to healthcare,” said Deb Autor, Chief Policy Officer at Hims & Hers. “Now is the time to harness new technologies to make care more proactive, personal, and accessible. Hims & Hers is setting a new standard for what responsible progress in healthcare looks like, and I’m excited to help shape the policies that will make that future a reality.”

Autor previously served as Deputy Commissioner for Global Regulatory Operations and Policy at the FDA, where she directed worldwide inspections, enforcement, and international engagement efforts. Earlier in her career, she led enforcement and policymaking for drug requirements at the FDA’s Office of Compliance for the Center for Drug Evaluation and Research, and represented the FDA as a trial attorney for the U.S. Department of Justice. More recently in the private sector, Autor’s roles include Global Head of Regulatory Excellence at AstraZeneca and CEO of Healthcare Innovation Catalysts.

“As digital health continues to evolve, the policies we shape today will define access, safety, and innovation for years to come,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Deb’s unparalleled regulatory experience and forward-looking vision make her the ideal leader to guide our engagement with stakeholders at this pivotal moment.”

Autor’s appointment marks a significant milestone in Hims & Hers’ evolution as the company continues to scale its engagement with regulators and policymakers. Her leadership will guide the company’s efforts to shape a modern regulatory framework that combines innovation with accountability, ensuring consumers can confidently access safe, effective, and trusted care online. Autor will also continue to serve as a member of the Hims & Hers Board of Directors.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.51
-3.87 (-1.67%)
AAPL  278.98
-5.17 (-1.82%)
AMD  215.33
-2.27 (-1.04%)
BAC  54.20
+0.10 (0.19%)
GOOG  317.46
-3.16 (-0.99%)
META  663.58
+23.98 (3.75%)
MSFT  477.41
-0.32 (-0.07%)
NVDA  182.54
+2.95 (1.65%)
ORCL  213.01
+5.28 (2.54%)
TSLA  447.79
+1.05 (0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.